IPO · 2026-02-24

How to Choose a Listing Venue for a Pre-IPO Company: HKEX, NYSE, or Nasdaq?

The calculus for a pre-IPO company choosing between Hong Kong, New York, or Nasdaq has fundamentally shifted in 2025, driven by three converging forces. First, the HKEX’s September 2024 consultation on listing regime enhancements for specialist technology companies (Chapter 18C) has been codified, lowering the minimum expected market capitalisation threshold for pre-commercial revenue companies from HKD 10 billion to HKD 6 billion (HKEX Consultation Paper, September 2024). Second, the US SEC’s finalised rules on clawback policies and enhanced disclosure for SPACs (SEC Release No. 34-100467, January 2025) have increased compliance costs for any issuer seeking a US listing. Third, the sustained divergence in valuation multiples between the Hang Seng Index and the S&P 500 — with the HSI trading at a trailing P/E of 9.8x versus the S&P 500’s 22.4x as of Q1 2025 (Bloomberg data) — means that the decision is no longer purely about liquidity, but about which investor base will ascribe the highest terminal value to a specific business model. For a CFO or sponsor structuring a pre-IPO round, this is not a binary choice; it is a multi-variable optimisation problem involving regulatory compatibility, currency risk, and the cost of capital.

HKEX Chapter 18C and the New Economy Pathway

The HKEX’s amended Chapter 18C, effective 1 January 2025, now provides a clearer path for pre-revenue technology companies. The key change is the reduction in the minimum expected market capitalisation at listing from HKD 10 billion to HKD 6 billion for companies with a minimum annual revenue of HKD 250 million. For companies with no revenue, the threshold remains at HKD 10 billion, but the market capitalisation-to-R&D expenditure ratio has been relaxed from 2.5x to 2.0x (HKEX Listing Decision LD145-2024). This directly impacts pre-IPO valuations: a biotech or AI company targeting a HKD 8 billion pre-money valuation in its Series D can now realistically plan for a Main Board listing under Chapter 18C, whereas under the old rules, it would have needed a minimum HKD 10 billion valuation, forcing it to consider a US listing or a later round.

The sponsor liability regime under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (SFC Code, para 17.6) remains the most stringent in any major listing venue. A sponsor must conduct independent due diligence on every material fact in the prospectus, with personal liability for the sponsor’s responsible officers. In practice, this means a pre-IPO company targeting HKEX must budget for sponsor fees of HKD 15-25 million for a standard Main Board IPO, versus USD 3-5 million (approximately HKD 23-39 million) for a US IPO, but the US fees include a higher proportion of underwriting commissions. The critical difference is timeline: HKEX sponsor due diligence typically requires 6-9 months of pre-filing work, while a US S-1 filing can be prepared in 4-6 months, though the SEC’s review process can add another 3-4 months.

US SEC Rules: Clawback and SPAC Disclosure

For a pre-IPO company considering NYSE or Nasdaq, the SEC’s finalised clawback rules require listed companies to recover erroneously awarded compensation from current and former executive officers in the event of a financial restatement. This applies to all listed companies, including newly listed ones, from the date of listing. The compliance burden is not trivial: a pre-IPO company must have its compensation clawback policy drafted and approved by the board before the effective date of the registration statement. The SEC’s enhanced SPAC disclosure rules (SEC Release No. 34-100467) also impose additional requirements on any issuer that has previously been a SPAC target or is considering a de-SPAC transaction. For a pre-IPO company that has received funding from a SPAC sponsor or has a SPAC-related warrant structure, the disclosure requirements now extend to detailed projections, fairness opinions, and sponsor compensation. This has made the de-SPAC route less attractive for Chinese issuers: in 2024, only 3 Chinese companies completed de-SPAC listings on Nasdaq, down from 12 in 2021 (Dealogic data).

Valuation Mechanics and Currency Risk

The Multiples Gap and Sectoral Arbitrage

The persistent valuation discount of Hong Kong-listed equities relative to US-listed peers creates a clear trade-off. As of Q1 2025, the average forward P/E for technology companies listed on the HKEX Main Board is 14.2x, compared to 28.6x for comparable companies on Nasdaq (Bloomberg consensus data). This gap is most pronounced for high-growth software and AI companies: a pre-IPO AI company with a 40% revenue growth rate might achieve a 12x revenue multiple on Nasdaq, but only 6x on the HKEX. However, the gap narrows for sectors with strong local demand, such as consumer staples and healthcare, where HKEX-listed companies trade at a premium to US-listed Chinese ADRs.

The currency risk is a structural factor often underestimated by pre-IPO CFOs. A company listing on NYSE or Nasdaq will raise capital in USD, but its operating expenses and revenue may be predominantly in RMB or HKD. This creates a natural currency mismatch that must be hedged. The cost of a 12-month USD/HKD forward contract is approximately 50-80 bps (Bloomberg FX data), while RMB/USD hedging can cost 150-250 bps depending on the tenor. For a company raising USD 100 million, this adds USD 500,000 to USD 2.5 million in annual hedging costs. In contrast, a HKEX listing raises HKD, which is pegged to the USD at 7.75-7.85, eliminating the currency mismatch for companies with HKD-based operations.

Pre-IPO Valuation Anchoring and the Sponsor’s Role

The pre-IPO valuation is not set in a vacuum; it is anchored to the expected listing valuation, which in turn is a function of the venue’s investor base. A pre-IPO round at a HKD 8 billion valuation for a HKEX-bound company must be supported by a credible sponsor’s valuation model that demonstrates a path to a HKD 10-12 billion listing valuation within 12-18 months. The HKEX’s Listing Rule 11.06 requires that the issuer’s market capitalisation at the time of listing be at least HKD 500 million for the Main Board, but the sponsor must also satisfy the HKEX that the valuation is reasonable. In practice, this means the pre-IPO round must be priced at a discount of 20-30% to the expected listing price, consistent with the market practice for pre-IPO placements (HKEX Guidance Letter GL36-12).

For a US listing, the pre-IPO round is typically priced at a discount of 15-25% to the IPO price, but the SEC does not impose a specific valuation test. Instead, the underwriter’s due diligence focuses on the fairness of the offering price relative to the company’s financial condition and market comparables. This gives more flexibility to a pre-IPO company to set a higher pre-money valuation, but it also increases the risk of a down-round if the IPO is delayed or market conditions deteriorate.

Structural Considerations: VIE, Cayman, and Dual-Class Shares

VIE Structure and the HKEX’s Position

For a PRC-incorporated company with foreign ownership restrictions, the VIE (Variable Interest Entity) structure remains the dominant vehicle for both HKEX and US listings. However, the HKEX’s position on VIE structures has evolved. In its 2023 guidance (HKEX Guidance Letter GL112-23), the HKEX clarified that it will accept VIE structures only where the PRC law restricts foreign ownership in the specific industry. This means a pre-IPO company operating in a fully open sector (e.g., e-commerce, software) cannot use a VIE structure for a HKEX listing; it must use a direct shareholding structure. The US exchanges do not impose this restriction, meaning a VIE structure is available for any PRC company, regardless of industry. This is a critical structural differentiator: a pre-IPO company in a non-restricted sector that wishes to maintain a VIE structure for tax or control reasons must choose a US listing.

The Cayman Islands remains the preferred jurisdiction for the holding company in both venues. For a HKEX listing, the issuer must be incorporated in Hong Kong, China, Bermuda, or the Cayman Islands (HKEX Listing Rule 19.04). For a US listing, the issuer can be incorporated in any jurisdiction that the SEC accepts, with Cayman being the most common for Chinese companies due to its flexible corporate law and tax neutrality. The choice of Cayman as the listing vehicle does not affect the venue decision, but it does affect the corporate governance requirements: a Cayman company listing on the HKEX must comply with the HKEX’s Corporate Governance Code (Appendix 14), which requires a minimum of three independent non-executive directors and a nomination committee chaired by an independent director. The NYSE and Nasdaq have similar but not identical requirements; the Nasdaq requires a majority of independent directors for listed companies, while the NYSE requires a majority plus a compensation committee composed entirely of independent directors.

The HKEX’s Chapter 8A, introduced in 2018, permits dual-class share structures for new economy companies, but with significant restrictions. The weighted voting rights (WVR) beneficiary must be a director of the company and hold no more than 10x the voting power of ordinary shares. The HKEX also imposes a sunset clause: WVR must lapse upon the beneficiary’s death, resignation, or transfer of shares. The US exchanges allow dual-class structures with fewer restrictions: Nasdaq does not impose a maximum voting ratio, and there is no mandatory sunset clause. This makes Nasdaq the preferred venue for founders who wish to retain control with a minority economic stake. For a pre-IPO company with a founder who holds 15% of the equity but wants 60% voting control, a US listing is the only viable option. The HKEX’s 10:1 cap means the founder would need to hold at least 6% of the equity to achieve the same voting power, which may not be feasible if the pre-IPO round dilutes the founder’s stake below that threshold.

Closing: Three Actionable Takeaways

Match the venue to the sector and revenue profile: A pre-revenue biotech or AI company with a market capitalisation of HKD 6-10 billion should prioritise HKEX under Chapter 18C for its lower sponsor liability and currency alignment, while a high-growth software company with a valuation above HKD 10 billion and a need for a dual-class structure should target Nasdaq for its higher multiples and flexible governance.
Budget for the full cost of capital, not just the underwriting spread: Include sponsor fees, legal costs, hedging expenses, and ongoing compliance costs in the venue comparison; a HKEX listing typically costs HKD 80-120 million in total fees for a HKD 1 billion offering, while a US listing costs USD 12-18 million (approximately HKD 93-140 million), with the difference largely driven by higher legal and accounting fees for SEC compliance.
Assess the VIE structural constraint early: If the company operates in a sector with no PRC foreign ownership restrictions, a HKEX listing will require a direct shareholding structure, which may have tax implications for existing offshore investors; if the VIE structure is non-negotiable, the only viable venue is NYSE or Nasdaq.